HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
Unrescetable Hepatocellular Carcinoma
DRUG: HAIC+Cadonilimab+Bevacizumab
Overall response rate ( ORR) per RECIST 1.1, Defined as proportion of patients who have a best response of CR or PR, Up to 1 year
Overall survival (OS), Defined as the time from enrollment to death from any cause, Up to two years|Progress Free Survival (PFS), Defined as the time from enrollment to disease progression or death (whichever occurs first), Up to two years|Adverse Events (AEs), Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, Up to two years|Disease Control Rate (DCR) per RECIST 1.1, Defined as proportion of patients who have CR or PR or SD, Up to 1 year
An open label, single-arm, single center, phase II study evaluating HAIC combined with cadonilimab and bevacizumab as first-line therapy in unresectable hepatocellular carcinoma